BackEucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Overview

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Net Tangible Assets

Latest net tangible assets for EUCRU: $8.5M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$8.54M
255.49% YoYΔ $14.03M vs prior year quarter

Peer average

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Net Tangible Assets History

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) vs. peers: Net Tangible Assets Comparison

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) (EUCRU) FAQ

The latest net tangible assets for EUCRU is $8.5M as of December 2022. That compares with $-5.5M in the prior-year period — up 255.5% year over year. Investors often review this figure alongside Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EUCRU's net tangible assets moved from $-5.5M to $8.5M — a 255.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s operating scale or balance-sheet position.

A net tangible assets figure of $8.5M for EUCRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EUCRU's net tangible assets ($8.5M), review year-over-year change from $-5.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.